<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080805</url>
  </required_header>
  <id_info>
    <org_study_id>HR-BLTN-Ⅲ-MBC</org_study_id>
    <nct_id>NCT03080805</nct_id>
  </id_info>
  <brief_title>Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)</brief_title>
  <official_title>A Randomised, Open-label, Parallel Controlled, Multicentre, Phase 3 Clinical Trial of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This&#xD;
      study is a randomized,open-label,multi-center,active-controlled, parallel design study of the&#xD;
      combination of pyrotinib and capecitabine versus Lapatinib plus capecitabine in HER2+ MBC&#xD;
      patients, who have prior received taxane and trastuzumab.Patients will be randomized in a 1:1&#xD;
      ratio to one of the following treatment arms.Arm A: pyrotinib (400 mg once daily) +&#xD;
      capecitabine (1000 mg/m^2 twice daily),Arm B: Lapatinib (1250 mg once daily) + capecitabine&#xD;
      (1000 mg/m^2 twice daily).Patients will receive either arm of therapy until disease&#xD;
      progression, unacceptable toxicity, or withdrawalof consent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>Estimated 10 months</time_frame>
    <description>From infromed consent to progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: AE</measure>
    <time_frame>AE recorded from infromed consent to 28 days after treatment completion</time_frame>
    <description>AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Estimated 30 months</time_frame>
    <description>From infromed consent to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Estimated 10 months</time_frame>
    <description>CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Estimated 10 months</time_frame>
    <description>From infromed consent to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Estimated 10 months</time_frame>
    <description>CR+PR+SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit rate (CBR)</measure>
    <time_frame>Estimated 10 months</time_frame>
    <description>CR+PR+SD≥24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>HER2 Positive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pyrotinib Plus Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib Plus Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib Plus Capecitabine</intervention_name>
    <description>pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/ m^2 BID)</description>
    <arm_group_label>Pyrotinib Plus Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib Plus Capecitabine</intervention_name>
    <description>Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)</description>
    <arm_group_label>Lapatinib Plus Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 and ≤70 years.&#xD;
&#xD;
          2. ECOG performance status of 0 to 1.&#xD;
&#xD;
          3. Life expectancy of more than 12 weeks.&#xD;
&#xD;
          4. According to RECIST 1.1, at least one measurable lesion exists&#xD;
&#xD;
          5. Histologically or cytologic confirmed HER2 positive metastatic breast cancer.&#xD;
&#xD;
          6. Prior treatment with trastuzumab (≥2 cycles in metastatic setting, or&#xD;
&#xD;
             ≥3 months in adjuvant/neoadjuvant setting) and Taxane(≥2 cycles in any setting or&#xD;
             untill unendurable AE or progression during treatment).&#xD;
&#xD;
          7. Previously reveived ≤2 chemotherapy regimens in metastasis setting;&#xD;
&#xD;
          8. Required laboratory values including following parameters:&#xD;
&#xD;
             ANC: ≥ 1.5 x 10^9/L; Platelet count: ≥ 90 x 10^9/L; Hemoglobin: ≥ 90 g/L; Total&#xD;
             bilirubin: ≤ 1.5 x upper limit of normal (ULN); ALT and AST: ≤ 2 x ULN(patients with&#xD;
             liver metastases: ≤5 x ULN); BUN and Creatinine:&#xD;
&#xD;
             ≤ 1x ULN;CCR≥50 mL/min;LVEF: ≥ 50%;QTcF: &lt; 450 ms (male)，&lt; 470 ms（female）;&#xD;
&#xD;
          9. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received capecitabine in metastatic setting;&#xD;
&#xD;
          2. Received HER2 targeted tyrosine kinase inhibitor (including Lapatinib, Neratinib and&#xD;
             Pyrotinib);&#xD;
&#xD;
          3. Cumulated dosage of Doxorubincin &gt;400 mg/m^2 or Epirubicin &gt;800 mg/m^2 or equal dosage&#xD;
             of other anthracycline drugs in adjuvant/neoadjuvant/metastatic setting );&#xD;
&#xD;
          4. Received surgery，chemotherapy,radiotherapy or target therapy within 28 days prior to&#xD;
             randomization. Received hormone therapy within 7 days prior to randomization;&#xD;
&#xD;
          5. Participated in other clinical trial within 28 days prior to randomization.&#xD;
&#xD;
          6. Known dihydro pyrimidine dehydrogenase（DPD）defect;&#xD;
&#xD;
          7. CT or MRI confirmed brain metastases;&#xD;
&#xD;
          8. Bone or skin lesion as unique target lesion;&#xD;
&#xD;
          9. Second malignancies within 5 years, except for cured skin basal cell&#xD;
             carcinoma,carcinoma in-situ of uterine cervix and squamous-cell carcinoma;&#xD;
&#xD;
         10. Factors influencing the usage of oral administration (e.g. unable to swallow, chronic&#xD;
             diarrhea and intestinal obstruction, etc.);&#xD;
&#xD;
         11. Uncontrolled third space effusion (such as pleural fluid and ascites) by drainage or&#xD;
             other clinical intervention;&#xD;
&#xD;
         12. Receiving any other anti-tumour therapy after informed consent;&#xD;
&#xD;
         13. Unprogressed after or during the last anti-tumour therapy,according to RECIST1.1;&#xD;
&#xD;
         14. History of any kind of Heart disease,including 1)Angina pectoris; (2) Arrhythmia&#xD;
             required medication or with clinical significance; (3) Myocardial infarction; (4)&#xD;
             Heart failure; (5) Any other heart disease judged by researcher as not suitable for&#xD;
             participating in this study, etc;&#xD;
&#xD;
         15. History of Immunodeficiency, acquired or congenital immunodeficiency (HIV positive)&#xD;
             ,history of organ transplantation;&#xD;
&#xD;
         16. History of neurological or psychiatric disorders, including epilepsy or dementia;&#xD;
&#xD;
         17. Concomitant disease judged by investigators that may bring serious harm to the safety&#xD;
             of patients or the completion of this study;&#xD;
&#xD;
         18. All female patients in breastfeeding period or in child-bearing period or with&#xD;
             positive pregnancy test result or refusing to take a reliable method of birth control&#xD;
             during the study;&#xD;
&#xD;
         19. Any other situations judged by investigator as not suitable for participating in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Institute and Hospital,Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

